/Zoetis%20Inc%20logo%20on%20phone-by%20viewimage%20via%20Shutterstock.jpg)
Parsippany, New Jersey-based Zoetis Inc. (ZTS) discovers, develops, and commercializes animal health medicines, vaccines, and diagnostic products and services. With a market cap of $68.1 billion, Zoetis operates as the world's largest producer of medicines and vaccines for pets and livestock, with operations spanning over 100 countries in North America, Europe, and internationally.
The animal healthcare giant is set to announce its second-quarter results before the market opens on Tuesday, Aug. 5. Ahead of the event, analysts expect ZTS to report an adjusted profit of $1.61 per share, up 3.2% from $1.56 per share reported in the year-ago quarter. ZTS has surpassed the Street’s bottom-line estimates in each of the past four quarters.
For fiscal 2025, its earnings are expected to be $6.26 per share, marking a 5.7% increase from $5.92 reported in fiscal 2024.

ZTS shares have plunged 17.2% over the past 52 weeks, notably lagging behind the S&P 500 Index’s ($SPX) 10.5% gains and the Healthcare Select Sector SPDR Fund’s (XLV) 10.4% dip during the same time frame

On June 18, shares of Zoetis fell over 3%, making it one of the biggest decliners in the S&P 500 for the day. The drop came after investment firm Stifel downgraded the stock from a "Buy" to a "Hold" rating. In its note, Stifel pointed to “developing headwinds” that could challenge the company's near-term performance.
Nonetheless, the consensus opinion on ZTS stock is extremely bullish, with a “Strong Buy” rating overall. Of the 15 analysts covering the stock, opinions include 12 “Strong Buys,” one “Moderate Buy,” and two “Hold.” Its mean price target of $198.28 implies an upswing potential of 30.8% from the current market prices.
On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.